Why the study?
Do sirolimus-eluting stents compared to paclitaxel-eluting stents reduce major adverse cardiac events in patients with coronary lesions?
Do sirolimus-eluting stents compared to paclitaxel-eluting stents reduce major adverse cardiac events in patients with coronary lesions?
In routine clinical practice, there was no significant difference in MACE between sirolimus-eluting and paclitaxel-eluting stents, though stent overlapping independently predicted MACE and TVR.
No takes yet. Share an insight, caveat, or question.
Similar MACE rates with SES versus PES in routine practice; leaves open superiority without randomized evidence.
Katritsis et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: